© 2022 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
June 09, 2012
Examination of the cost-effectiveness of rasagiline versus other approved first-line Parkinson disease therapies indicated that rasagiline was either cost saving or cost-effective in all cases.